Diagnostic or prognostic study
A microbiota pattern associated with cardiovascular events in secondary prevention: the CORDIOPREV study
- Prognostic study (secondary analysis of the CORDIOPREV clinical trial)
Authors' conclusion
These results reinforce the relationship between intestinal microbiota and CVD and suggest that a microbiota profile is associated with MACE in CHD patients, in addition to higher endotoxaemia.
Study context
- Population
- Patients with coronary heart disease (CHD) in the CORDIOPREV trial with available faecal samplestrial n = 1002
- Participants
- 679 patients
- Comparison
- Gut microbiota of CHD patients with vs without new MACE over 7 years
- MACEn = 132
- Outcome
- Baseline gut microbiota differences and a microbiota score associated with new MACE risk
- Follow-up
- 7 years
Performance
As reported in the abstract
MACE incidence by intestinal microbiota risk score (10 bacterial taxa, random survival forest)
Hazard ratio
2.01
95% CI 1.37–3.22
Intestinal microbiota risk score vs No MACE
HR 2.01 (95% CI 1.37–3.22)
- AUC, training set
- 65.2% (59.1%-71.3%)
- AUC, validation set
- 68.6% (59.3%-77.9%)
Further findings
Lipopolysaccharide (LPS) post-prandial fold change
- Greater LPS post-prandial fold change in the MACE group
- P = 0.005
Original publication
A microbiota pattern associated with cardiovascular events in secondary prevention: the CORDIOPREV study. Eur Heart J. Published 8 April 2025. doi:10.1093/eurheartj/ehaf181
Summarised from the published abstract; every number is checked against it